Last edition
News about "Bio-Thera Solutions "
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Bio-Thera Solutions | 27/07/2026 | By News Bureau | 106
Accord BioPharma has received US FDA approval for Immgolis and Immgolis Intri, the first golimumab biosimilars approved in the United States for rheumatoid arthritis and ulcerative colitis treatment.
Bio-Thera Solutions | 19/05/2026 | By News Bureau | 171
Bio-Thera Expands Partnership with Intas for BAT2506 Biosimilar in India
Bio-Thera has expanded its partnership with Intas Pharmaceuticals to commercialise BAT2506, a proposed golimumab biosimilar, in India.
Bio-Thera Solutions | 24/03/2026 | By News Bureau | 200
STADA and Bio-Thera Secure EU Marketing Approval for Golimumab Biosimilar Gotenfia
European Commission authorises Gotenfia, referencing Simponi, for multiple autoimmune diseases across EU and EEA markets.
Bio-Thera Solutions | 16/02/2026 | By News Bureau | 230
Bio-Thera, STADA Expand Biosimilars Alliance to Include Tocilizumab
Bio-Thera Solutions and STADA Arzneimittel have extended their biosimilars alliance to include tocilizumab, with Bio-Thera handling development and supply while STADA secures exclusive commercialization rights across Europe and select markets.
Bio-Thera Solutions | 25/08/2025 | By Mrinmoy Dey | 267
Bio-Thera Signs Exclusive Commercialization Deal with Dr. Reddy's for BAT2206 and BAT2506
Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506. Dr. Reddy's will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam.
Bio-Thera Solutions | 29/03/2025 | By Aishwarya | 272
Bio-Thera Solutions, Tabuk Pharmaceutical Partner to Commercialise BAT2206 in Saudi Arabia
Bio-Thera Solutions Inc. has partnered with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, for BAT2206, its ustekinumab biosimilar.
Bio-Thera Solutions | 26/12/2024 | By Abha | 979
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy